Interesting to note that Enmd has turned MKC-1 from a toxic drug into a "well-tolerated without evidence of cumulative toxicity" drug. They did it by their keen observation and anti-angiogenesis knowledge and applied it to MKC-1 to get some modest results. I hope the people at Roche are pleasantly surprised.
"We plan to evaluate our options for either randomized single- agent or combination studies in breast cancer once this study is complete." Does this mean a phase IIb study is next or possibly a phase III study? I really don't know.